Drug intelligence / Profile preview

MOC191

Development stage: Preclinical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intraperitoneal

Overview

MOC191 is a murine monoclonal antibody belonging to cluster 1 of anti-small-cell lung cancer (SCLC) monoclonal antibodies. It specifically binds to the neural cell adhesion molecule (NCAM) with high affinity. The drug was investigated for its efficacy in immunoscintigraphy of SCLC xenografts in a mouse model, where it was administered via intraperitoneal injection. While it demonstrated tumor uptake, its performance was less favorable compared to another antibody, 123C3, primarily because MOC191 is not internalized into tumor cells, unlike 123C3.

Targets

NCAM1 (Neural cell adhesion molecule 1)

Beyond the preview

Go deeper on MOC191.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MOC191.

Explore the full profile